Plant Comparison
Purple coneflower vs Chaga
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Purple coneflower and Chaga: they share 7 indicated uses (arthritis / joint pain, cold & flu, immune support, …); 3 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Purple coneflower | Chaga | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Cold & flu | 1/10 | 1/10 | Comparable evidence |
| Immune support | 1/10 | 2/10 | Comparable evidence |
| Infection (general) | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
| Wounds | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Lipophilic alkamides are considered key immunomodulatory and anti-inflammatory constituents, particularly concentrated in the root.
Antioxidant phenolic compounds contributing to the plant's immunomodulatory activity.
Water-soluble polysaccharides associated with immune-stimulating activity, particularly from the aerial parts.
Chaga's dark colour comes from melanin-like pigments; it also concentrates betulinic-acid-type triterpenes absorbed from its birch host, associated with antioxidant and anticancer research interest.
Immunomodulatory polysaccharides contributing to the traditional tonic and immune-support use.
Antioxidant phenolics contributing to chaga's free-radical-scavenging activity.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from immunomodulator action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anticancer action
inferred from immunomodulator action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Chaga-derived 3,4-DHBA protected against Parkinson's-related neurotoxicity (preclinical).
Chaga polysaccharide lowered lipids in vivo and in vitro.
Safety, Cautions & Contraindications
Generally considered safe, but caution advised for those with autoimmune conditions. Not recommended for long-term use (more than 8 weeks continuously).
Duke (2002) rates echinacea as +++ — among the most thoroughly documented herbal immunostimulants. It notes experimental and clinical evidence for immunostimulant, antiviral, and anti-inflammatory activities. Multiple species have been studied (E. purpurea, E. angustifolia, E. pallida), and Duke emphasizes that species identification in commercial products is often unreliable. Commission E approves E. purpurea for supporting immune function during colds and flu. Dose: 900 mg standardized extract daily in acute use; use should be limited to 8 weeks continuous. Contraindicated in autoimmune diseases (MS, lupus, HIV/AIDS), tuberculosis, and with immunosuppressive drugs (cyclosporine) (Duke, 2002).
Autoimmune conditions: Chaga can stimulate parts of the immune system—people with autoimmune diseases should be cautious.Blood thinners: Chaga contains compounds that may affect clotting—avoid large doses if on anticoagulants.Blood sugar meds: May slightly lower glucose—monitor if taking diabetes medication.Pregnancy & breastfeeding: Limited safety data—best avoided unless guided by a professional.Quality matters: Wild-harvested Chaga can accumulate heavy metals from trees and soil—source from reputable suppliers.
External Ids
Botanical Description
Robust perennial herb with a basal rosette of coarse, hairy, lance-shaped leaves and tall, sturdy flowering stems. Each stem bears a single large, daisy-like flower head with drooping (reflexed), rose-purple to pink ray florets surrounding a prominent, spiny, orange-brown central cone of disc florets.[4]
Parasitic wood-decay fungus (not a true plant) that grows almost entirely inside the trunk of living birch trees, visible externally only as a hard, black, cracked, charcoal-like mass (a sclerotium, sometimes called a 'conk') erupting through the bark. Unlike typical mushrooms, chaga has no true cap, gills or stem; its fertile spore-producing surface develops later, hidden beneath the bark after the tree dies.[1]
Habitat
Native to the tallgrass prairies, open woodland and dry meadows of central and eastern North America; widely cultivated worldwide as a garden and medicinal plant.[4]
Grows almost exclusively as a parasite on living birch trees in cold, northern temperate and boreal forests of Europe, Russia, North America and Asia.[1]
Harvesting
The flower heads are picked as they open, in summer; the root is dug in autumn from plants at least two to three years old, when its content of bioactive alkamides and caffeic acid derivatives is highest, then cleaned and dried.[4]
The hard black external mass (conk) is chopped or broken away from the living birch trunk, ideally without killing the tree, then dried and broken into pieces or ground for use; sustainable harvesting (leaving part of the conk to regrow) is recommended given the fungus's slow growth.
Traditional Uses
Echinacea root was widely used by Native American peoples as a remedy for infections, wounds, snakebite and toothache, and entered nineteenth-century Eclectic medicine as a broad anti-infective. It remains best known today, in standardised aerial-part or root extracts, as a supportive remedy for preventing and shortening the common cold and supporting immune function.[1, 4]
Chaga has a long traditional use in Russian, Siberian, Baltic and Scandinavian folk medicine as a tonic remedy for digestive complaints, immune support and general vitality, traditionally taken as a dark, tea-like decoction; this traditional tonic reputation is now studied for its antioxidant, immunomodulatory and anti-inflammatory properties.[1, 4]
Preparations
Fresh-pressed juice or standardised extract of the aerial parts or root, taken as tablets, drops or capsules at the first sign of a cold; the best-studied clinical form.
Dosage
Clinical trials for the common cold commonly use around 300-900 mg of standardised extract daily, started at the first sign of symptoms and continued for up to 7-10 days; continuous use beyond about 8 weeks is not recommended. Educational reference only, not a prescription.
Not documented
References
Drug Class Interactions
Not documented
Lookalikes Review
References & Sources
- Karsch-Völk, M., Barrett, B., Kiefer, D., Bauer, R. et al (2014) 'Echinacea for preventing and treating the common cold', Cochrane Database of Systematic Reviews, 2(2), pp. CD000530. doi:10.1002/14651858.CD000530.pub3 Meta-analysis / review
https://doi.org/10.1002/14651858.CD000530.pub3 - Kamin, W., Seifert, G., Zwiauer, K., Bonhoeffer, J. et al (2025) 'Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review', Frontiers in Pediatrics, 13, pp. 1423250. doi:10.3389/fped.2025.1423250 Meta-analysis / review
https://doi.org/10.3389/fped.2025.1423250 - Fashner, J., Ericson, K. and Werner, S (2012) 'Treatment of the common cold in children and adults', American Family Physician, 86(2), pp. 153-159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927/ Traditional / reference
https://pubmed.ncbi.nlm.nih.gov/22962927/ - Manayi, A., Vazirian, M. and Saeidnia, S (2015) 'Echinacea purpurea: Pharmacology, phytochemistry and analysis methods', Pharmacognosy Reviews, 9(17), pp. 63-72. doi:10.4103/0973-7847.156353 Meta-analysis / review
https://doi.org/10.4103/0973-7847.156353 - Burlou-Nagy, C., Banica, F., Jurca, T., Vicas, L.G., Marian, E., Muresan, M.E., Bacskay, I., Kiss, R., Feher, P. and Pallag, A (2022) 'Echinacea purpurea (L.) Moench: Biological and Pharmacological Properties. A Review', Plants, 11(9), pp. 1244. doi:10.3390/plants11091244 Meta-analysis / review
https://doi.org/10.3390/plants11091244 - Hall, H., Fahlman, M.M. and Engels, H.J (2007) 'Echinacea purpurea and mucosal immunity', International Journal of Sports Medicine, 28(9), pp. 792-797. doi:10.1055/s-2007-964895 Randomized trial
https://doi.org/10.1055/s-2007-964895 - Ross, S.M (2016) 'Echinacea purpurea: A Proprietary Extract of Echinacea purpurea Is Shown to be Safe and Effective in the Prevention of the Common Cold', Holistic Nursing Practice, 30(1), pp. 54-57. doi:10.1097/HNP.0000000000000130 Meta-analysis / review
https://doi.org/10.1097/HNP.0000000000000130 - Hudson, J.B (2011) 'Applications of the phytomedicine Echinacea purpurea (Purple Coneflower) in infectious diseases', Journal of Biomedicine & Biotechnology, 2012, pp. 769896. doi:10.1155/2012/769896 Meta-analysis / review
https://doi.org/10.1155/2012/769896 - Mishima, S., Saito, K., Maruyama, H., Inoue, M., Yamashita, T., Ishida, T. and Gu, Y (2004) 'Antioxidant and immuno-enhancing effects of Echinacea purpurea', Biological & Pharmaceutical Bulletin, 27(7), pp. 1004-1009. doi:10.1248/bpb.27.1004 Preclinical
https://doi.org/10.1248/bpb.27.1004 - Saunders, P.R., Smith, F. and Schusky, R.W (2007) 'Echinacea purpurea L. in children: safety, tolerability, compliance, and clinical effectiveness in upper respiratory tract infections', Canadian Journal of Physiology and Pharmacology, 85(11), pp. 1195-1199. doi:10.1139/Y07-103 Clinical study
https://doi.org/10.1139/Y07-103 - Micheli, L., Maggini, V., Ciampi, C., Gallo, E., Bogani, P., Fani, R., Pistelli, L., Ghelardini, C., Di Cesare Mannelli, L., De Leo, M. and Firenzuoli, F (2022) 'Echinacea purpurea against neuropathic pain: Alkamides versus polyphenols efficacy', Phytotherapy Research, 37(5), pp. 1911-1923. doi:10.1002/ptr.7709 Preclinical
https://doi.org/10.1002/ptr.7709 - Gholami, M., Amri, J., Pazhoohan, S. and Sadegh, M (2021) 'Anticonvulsive and anti-epileptogenesis effects of Echinacea purpurea root extract, an involvement of CB2 receptor', Journal of Complementary & Integrative Medicine, 19(4), pp. 879-886. doi:10.1515/jcim-2020-0219 Preclinical
https://doi.org/10.1515/jcim-2020-0219 - Awortwe, C., Bruckmueller, H., Kaehler, M. and Cascorbi, I (2021) 'Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters', Molecular Pharmaceutics, 18(4), pp. 1622-1633. doi:10.1021/acs.molpharmaceut.0c01075 Preclinical
https://doi.org/10.1021/acs.molpharmaceut.0c01075 - Perry, N.B., van Klink, J.W., Burgess, E.J. and Parmenter, G.A (1997) 'Alkamide levels in Echinacea purpurea: a rapid analytical method revealing differences among roots, rhizomes, stems, leaves and flowers', Planta Medica, 63(1), pp. 58-62. doi:10.1055/s-2006-957605 Preclinical
https://doi.org/10.1055/s-2006-957605 - Linde, K., Barrett, B., Wölkart, K., Bauer, R. and Melchart, D (2006) 'Echinacea for preventing and treating the common cold'. Traditional / reference
https://scholar.google.com/scholar?q=Echinacea%20for%20preventing%20and%20treating%20the%20common%20cold - Sharma, M., Schoop, R., Suter, A. and Schoop, W (2010) 'The possibility of prophylactic treatment of streptococcal pharyngotonsillitis with a standardized Echinacea preparation', 29(8), pp. 1025--1035. Traditional / reference
https://scholar.google.com/scholar?q=The%20possibility%20of%20prophylactic%20treatment%20of%20streptococcal%20pharyngotonsillitis%20with%20a%20standardized%20Echinacea%20preparation - World Health Organization (1999) 'WHO Monographs on Selected Medicinal Plants'. Traditional / reference
https://scholar.google.com/scholar?q=WHO%20Monographs%20on%20Selected%20Medicinal%20Plants - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Gorski, J.C., Huang, S.M., Pinto, A., Hamman, M.A., Hilligoss, J.K., Zaheer, N.A., Desai, M., Miller, M. and Hall, S.D (2004) 'The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo', Clinical Pharmacology and Therapeutics, 75(1), pp. 89-100. doi:10.1016/j.clpt.2003.09.013 Clinical study
https://doi.org/10.1016/j.clpt.2003.09.013
- Camilleri, E., Blundell, R., Baral, B., Karpinski, T.M. et al (2024) 'A brief overview of the medicinal and nutraceutical importance of Inonotus obliquus (chaga) mushrooms', Heliyon, 10(15), pp. e35638. doi:10.1016/j.heliyon.2024.e35638 Traditional / reference
https://doi.org/10.1016/j.heliyon.2024.e35638 - Lu, Y., Jia, Y., Xue, Z., Li, N. et al (2021) 'Recent Developments in Inonotus obliquus (Chaga mushroom) Polysaccharides: Isolation, Structural Characteristics, Biological Activities and Application', Polymers (Basel), 13(9), pp. 1441. doi:10.3390/polym13091441 Traditional / reference
https://doi.org/10.3390/polym13091441 - Kobus, Z., Krzywicka, M., Blicharz-Kania, A., Bosacka, A. et al (2024) 'Impact of Incorporating Dried Chaga Mushroom (Inonotus obliquus) into Gluten-Free Bread on Its Antioxidant and Sensory Characteristics', Molecules, 29(16), pp. 3801. doi:10.3390/molecules29163801 Preclinical
https://doi.org/10.3390/molecules29163801 - Szychowski, K.A., Skora, B., Pomianek, T. and Gminski, J (2020) 'Inonotus obliquus - from folk medicine to clinical use', Journal of Traditional and Complementary Medicine, 11(4), pp. 293-302. doi:10.1016/j.jtcme.2020.08.003 Meta-analysis / review
https://doi.org/10.1016/j.jtcme.2020.08.003 - Javed, S., Mitchell, K., Sidsworth, D., Sellers, S.L., Reutens-Hernandez, J., Massicotte, H.B., Egger, K.N., Lee, C.H. and Payne, G.W (2019) 'Inonotus obliquus attenuates histamine-induced microvascular inflammation', PLoS One, 14(8), pp. e0220776. doi:10.1371/journal.pone.0220776 Preclinical
https://doi.org/10.1371/journal.pone.0220776 - Zou, C., Hou, Z., Bai, M., Guo, R., Lin, B., Wang, X., Huang, X. and Song, S (2020) 'Highly modified steroids from Inonotus obliquus', Organic & Biomolecular Chemistry, 18(20), pp. 3908-3916. doi:10.1039/d0ob00474j Preclinical
https://doi.org/10.1039/d0ob00474j - Zhong, X.H., Ren, K., Lu, S.J., Yang, S.Y. and Sun, D.Z (2009) 'Progress of research on Inonotus obliquus', Chinese Journal of Integrative Medicine, 15(2), pp. 156-160. doi:10.1007/s11655-009-0156-2 Meta-analysis / review
https://doi.org/10.1007/s11655-009-0156-2 - Burmasova, M.A., Utebaeva, A.A., Sysoeva, E.V. and Sysoeva, M.A (2019) 'Melanins of Inonotus obliquus: bifidogenic and antioxidant properties', Biomolecules, 9(6), pp. 248. doi:10.3390/biom9060248 Preclinical
https://doi.org/10.3390/biom9060248 - Sun, Y., Deng, X., Li, Z., Dong, Y., Jiang, W., Ma, Y., Zhou, W., Zhu, T., Wang, G., Liu, S. and Hu, B (2022) 'Polysaccharide derived from Inonotus obliquus inhibits lipopolysaccharide-induced acute endometritis in mice', American Journal of Translational Research, 14(11), pp. 8332-8342. Preclinical
https://scholar.google.com/scholar?q=Polysaccharide%20derived%20from%20Inonotus%20obliquus%20inhibits%20lipopolysaccharide-induced%20acute%20endometritis%20in%20mice - Ishfaq, P.M., Mishra, S., Mishra, A., Ahmad, Z., Gayen, S., Jain, S.K., Tripathi, S. and Mishra, S.K (2022) 'Inonotus obliquus aqueous extract prevents histopathological alterations in liver induced by environmental toxicant Microcystin', Current Research in Pharmacology and Drug Discovery, 3, pp. 100118. doi:10.1016/j.crphar.2022.100118 Preclinical
https://doi.org/10.1016/j.crphar.2022.100118 - Peng, A., Liu, S., Fang, L., Zhu, Z., Zhou, Y., Yue, S., Ma, Z., Liu, X., Xue, S., Qiu, Y. and Qi, R (2022) 'Inonotus obliquus and its bioactive compounds alleviate non-alcoholic fatty liver disease via regulating FXR/SHP/SREBP-1c axis', European Journal of Pharmacology, 921, pp. 174841. doi:10.1016/j.ejphar.2022.174841 Preclinical
https://doi.org/10.1016/j.ejphar.2022.174841 - Zhang, Y., Liu, Q., Sun, Y. and Jiang, J (2023) 'Inonotus obliquus sclerotia epidermis were different from internal tissues in compound composition, antioxidant activity, and associated fungi', FEMS Microbiology Letters, 370, pp. fnad126. doi:10.1093/femsle/fnad126 Preclinical
https://doi.org/10.1093/femsle/fnad126 - Yu, S., Lai, Z., Xue, H., Zhu, J., Yue, G., Wang, J. and Jin, L.H (2024) 'Inonotus obliquus aqueous extract inhibits intestinal inflammation and insulin metabolism defects in Drosophila', Toxicology Mechanisms and Methods, 34(9), pp. 970-984. doi:10.1080/15376516.2024.2368795 Preclinical
https://doi.org/10.1080/15376516.2024.2368795 - Wold, C.W. and Christopoulos, P. and Arias, M. and Dzovor, D.E. and Øynebråten, I. and Corthay, A. and Inngjerdingen, K.T (2024) 'Fungal polysaccharides from Inonotus obliquus are agonists for Toll-like receptors and induce macrophage anti-cancer activity', Communications Biology. doi:10.1038/s42003-024-05853-y Preclinical
https://doi.org/10.1038/s42003-024-05853-y - Li, J. and Qu, C. and Li, F. and Chen, Y. and Zheng, J. and Xiao, Y. and Jin, Q. and Jin, G. and Huang, X. and Jin, D (2021) 'Inonotus obliquus Polysaccharide Ameliorates Azoxymethane/Dextran Sulfate Sodium-Induced Colitis-Associated Cancer in Mice via Activation of the NLRP3 Inflammasome', Frontiers in Pharmacology. doi:10.3389/fphar.2020.621835 Preclinical
https://doi.org/10.3389/fphar.2020.621835 - Wold, C.W. and Gerwick, W.H. and Wangensteen, H. and Inngjerdingen, K.T (2020) 'Bioactive triterpenoids and water-soluble melanin from Inonotus obliquus (Chaga) with immunomodulatory activity', Journal of Functional Foods. doi:10.1016/j.jff.2020.104025 Preclinical
https://doi.org/10.1016/j.jff.2020.104025 - Kim, J. and Yang, S. and Hwang, A.Y. and Cho, H. and Hwang, K.T (2020) 'Composition of Triterpenoids in Inonotus obliquus and Their Anti-Proliferative Activity on Cancer Cell Lines', Molecules. doi:10.3390/molecules25184066 Preclinical
https://doi.org/10.3390/molecules25184066 - Duru, K.C. and Kovaleva, E.G. and Данилова, И.Г. and Bijl, P.V.D (2019) 'The pharmacological potential and possible molecular mechanisms of action of Inonotus obliquus from preclinical studies', Phytotherapy Research. doi:10.1002/ptr.6384 Preclinical
https://doi.org/10.1002/ptr.6384 - Hu, Y. and Teng, C. and Yu, S. and Wang, X. and Liang, J. and Bai, X. and Dong, L. and Song, T. and Yu, M. and Qu, J (2017) 'Inonotus obliquus polysaccharide regulates gut microbiota of chronic pancreatitis in mice', AMB Express. doi:10.1186/s13568-017-0341-1 Preclinical
https://doi.org/10.1186/s13568-017-0341-1 - Chou, Y. and Kan, W. and Chang, C. and Peng, Y. and Wang, H. and Yu, W. and Cheng, Y. and Jhang, Y. and Liu, H. and Chuu, J (2016) 'Renal Protective Effects of Low Molecular Weight of Inonotus obliquus Polysaccharide (LIOP) on HFD/STZ-Induced Nephropathy in Mice', International Journal of Molecular Sciences. doi:10.3390/ijms17091535 Preclinical
https://doi.org/10.3390/ijms17091535 - Arata, S. and Watanabe, J. and Maeda, M. and Yamamoto, M. and Matsuhashi, H. and Mochizuki, M. and Kagami, N. and Honda, K. and Inagaki, M (2016) 'Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice', Heliyon. doi:10.1016/j.heliyon.2016.e00111 Preclinical
https://doi.org/10.1016/j.heliyon.2016.e00111 - Lee, K.R. and Lee, J.S. and Kim, Y.R. and Song, I.G. and Hong, E.K (2014) 'Polysaccharide from Inonotus obliquus inhibits migration and invasion in B16-F10 cells by suppressing MMP-2 and MMP-9 via downregulation of NF-κB signaling pathway', Oncology Reports. doi:10.3892/or.2014.3103 Preclinical
https://doi.org/10.3892/or.2014.3103 - Song, F. and Liu, Y. and Kong, X. and Chang, W. and Song, G (2013) 'Progress on Understanding the Anticancer Mechanisms of Medicinal Mushroom: Inonotus Obliquus', Asian Pacific Journal of Cancer Prevention. doi:10.7314/apjcp.2013.14.3.1571 Preclinical
https://doi.org/10.7314/apjcp.2013.14.3.1571 - Gunjima, K. and Tomiyama, R. and Takakura, K. and Yamada, T. and Hashida, K. and Nakamura, Y. and Konishi, T. and Matsugo, S. and Hori, O (2013) '3,4‐Dihydroxybenzalacetone Protects Against Parkinson's Disease‐Related Neurotoxin 6‐OHDA Through Akt/Nrf2/Glutathione Pathway', Journal of Cellular Biochemistry. doi:10.1002/jcb.24643 Preclinical
https://doi.org/10.1002/jcb.24643 - Geng, Y. and Lu, Z. and Huang, W. and Xu, H. and Shi, J. and Xu, Z (2013) 'Bioassay-Guided Isolation of DPP-4 Inhibitory Fractions from Extracts of Submerged Cultured of Inonotus obliquus', Molecules. doi:10.3390/molecules18011150 Preclinical
https://doi.org/10.3390/molecules18011150 - Zhang, L. and Fan, C. and Liu, S. and Zang, Z. and Jiao, L. and Zhang, L (2011) 'Chemical composition and antitumor activity of polysaccharide from Inonotus obliquus', Journal of Medicinal Plants Research. doi:10.5897/jmpr.9000346 Preclinical
https://doi.org/10.5897/jmpr.9000346 - Choi, S. and Hur, S.J. and An, C.S. and Jeon, Y.H. and Jeoung, Y.J. and Bak, J.P. and Lim, B.O (2010) 'Anti-Inflammatory Effects ofInonotus obliquusin Colitis Induced by Dextran Sodium Sulfate', Journal of Biomedicine and Biotechnology. doi:10.1155/2010/943516 Preclinical
https://doi.org/10.1155/2010/943516 - Youn, M. and Kim, J. and Park, S. and Kim, Y. and Kim, S. and Lee, J.S. and Chai, K.Y. and Kim, H. and Cui, M. and So, H.S. and Kim, K. and Park, R (2008) 'Chaga mushroom (Inonotus obliquus ) induces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells', World Journal of Gastroenterology. doi:10.3748/wjg.14.511 Preclinical
https://doi.org/10.3748/wjg.14.511 - Nakajima, Y. and Sato, Y. and Konishi, T (2007) 'Antioxidant Small Phenolic Ingredients in Inonotus obliquus (persoon) Pilat (Chaga)', Chemical and Pharmaceutical Bulletin. doi:10.1248/cpb.55.1222 Preclinical
https://doi.org/10.1248/cpb.55.1222 - Kim, H. and Yoon, D. and Kim, C. and Shrestha, B. and Chang, W. and Lim, S. and Lee, W. and Han, S. and Lee, J. and Lim, M. and Kim, G. and Choi, S. and Song, W.O. and Sung, J. and Hwang, K (2007) 'Ethanol Extract of Inonotus obliquus Inhibits Lipopolysaccharide-Induced Inflammation in RAW 264.7 Macrophage Cells', Journal of Medicinal Food. doi:10.1089/jmf.2006.156 Preclinical
https://doi.org/10.1089/jmf.2006.156 - Mizuno, T. and Zhuang, C. and Abe, K. and Okamoto, H. and Kiho, T. and Ukai, S. and Leclerc, S. and Meijer, L (1999) 'Antitumor and Hypoglycemic Activities of Polysaccharides from the Sclerotia and Mycelia of Inonotus obliquus (Pers.: Fr.) Pil. (Aphyllophoromycetideae)', International journal of medicinal mushrooms. doi:10.1615/intjmedmushr.v1.i4.20 Preclinical
https://doi.org/10.1615/intjmedmushr.v1.i4.20 - Su, L. and Xin, C. and Yang, J. and Dong, L. and Mei, H. and Dai, X. and Wang, Q (2022) 'A polysaccharide from Inonotus obliquus ameliorates intestinal barrier dysfunction in mice with type 2 diabetes mellitus', International Journal of Biological Macromolecules. doi:10.1016/j.ijbiomac.2022.06.071 Preclinical
https://doi.org/10.1016/j.ijbiomac.2022.06.071 - Yang, M. and Hu, D. and Cui, Z. and Li, H. and Man, C. and Jiang, Y (2021) 'Lipid-Lowering Effects of Inonotus obliquus Polysaccharide In Vivo and In Vitro', Foods. doi:10.3390/foods10123085 Preclinical
https://doi.org/10.3390/foods10123085 - Wang, J. and Hu, W. and Li, L. and Huang, X. and Liu, Y. and Wang, D. and Teng, L (2017) 'Antidiabetic activities of polysaccharides separated from Inonotus obliquus via the modulation of oxidative stress in mice with streptozotocin-induced diabetes', PLoS ONE. doi:10.1371/journal.pone.0180476 Preclinical
https://doi.org/10.1371/journal.pone.0180476 - Giridharan, V.V. and Thandavarayan, R.A. and Konishi, T (2011) 'Amelioration of scopolamine induced cognitive dysfunction and oxidative stress by Inonotus obliquus– a medicinal mushroom', Food & Function. doi:10.1039/c1fo10037h Preclinical
https://doi.org/10.1039/c1fo10037h - Lee, J. and Hyun, C (2014) 'Insulin‐Sensitizing and Beneficial Lipid‐Metabolic Effects of the Water‐Soluble Melanin Complex Extracted from Inonotus obliquus', Phytotherapy Research. doi:10.1002/ptr.5131 Preclinical
https://doi.org/10.1002/ptr.5131 - Kim, Y (2005) 'Immunomodulatory Activity of the Water Extract from Medicinal MushroomInonotus obliquus', Mycobiology. doi:10.4489/myco.2005.33.3.158 Preclinical
https://doi.org/10.4489/myco.2005.33.3.158 - Géry, A., Dubreule, C., André, V., Rioult, J.P., Bouchart, V., Heutte, N., Eldin de Pécoulas, P., Krivomaz, T. and Garon, D (2018) 'Chaga (Inonotus obliquus), a future potential medicinal fungus in oncology? A chemical study and a comparison of the cytotoxicity against human lung adenocarcinoma cells (A549) and human bronchial epithelial cells (BEAS-2B)', 17(3), pp. 832--843. doi:10.1177/1534735418757912 Traditional / reference
https://doi.org/10.1177/1534735418757912 - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Shashkina, M.Ya., Shashkin, P.N. and Sergeev, A.V (2006) 'Chemical and medicobiological properties of chaga', 40(10), pp. 560--568. Traditional / reference
https://scholar.google.com/scholar?q=Chemical%20and%20medicobiological%20properties%20of%20chaga - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.